Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This study is a randomized, open, parallel controlled clinical trial. The main purpose of
this study was to compare the changes in body weight/body mass index (BMI) before and after
treatment between the two groups of patients with NST full-course nutritional management and
without NST full-course nutritional management.
The secondary objective was to compare the quality of life, nutritional status, immune
function and inflammatory response, adverse reactions of radiotherapy and chemotherapy, and
short-term/long-term efficacy between the two groups.
The treatment plan was: esophageal cancer with routine nutrition guidance as the control
group, and the NST whole-process intervention guidance as the experimental group.
1. Experimental group: NST whole-course intervention
1. Nutritionists formulate nutritional programs and manage them in a refined manner. On the
basis of the patient's natural diet (food and homogenate meal), enteral nutritional
preparations or parenteral nutritional supplements are given according to the patient's
gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d,
protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or
ostomy, oral feeding is preferred; severe obstruction of eating or oral can not meet the
target nutrition, choose tube feeding or ostomy. When it is expected that enteral
nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose
parenteral nutrition. The enteral nutritional preparation adopts the whole protein
enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation
Ruineng, and/or whey protein powder.
2. Radiotherapy
3. Chemotherapy 2. Control group: routine nutrition guidance for esophageal cancer
(1) Nutritional therapy: The nutritional program was the same as that of the experimental
group, and the patients performed it themselves.
(2) Concurrent chemoradiotherapy: the same as the experimental group.
Efficacy evaluation:
1. Body weight and body mass index (BMI)
2. Quality of life score (EORTCQLQ-C30)
3. Nutritional status
4. Immune function and inflammatory response (total lymphocytes, CRP, IL-6)
(4) Intestinal mucosal barrier and intestinal flora (5) Adverse reactions of radiotherapy and
chemotherapy (6) Short-term/long-term efficacy (5) Evaluation of treatment side effects (6)
Short-term/long-term efficacy
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University